Screening for kidney disease on World Kidney Day in Jalisco, Mexico

Journal of Nephrology

Volumn 23, Issue 2, 2010, Pages 224-230

  Garcia Garcia, Guillermo ^a   Marquez Magaña, Isela ^a   Renoirte Lopez, Karina ^a   Perez Cortes, Gustavo ^b   Gutierrez, M Luisa Salazar ^b   Klarenbach, Scott ^c   Lloyd, Anita ^c   Tonelli, Marcello ^c  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CKD; Screening; World Kidney Day

Indexed keywords

CREATININE;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEXICO; PREVALENCE; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; URINALYSIS; UROGENITAL TRACT DISEASE; WAIST CIRCUMFERENCE;

ADULT; AGED; BIOLOGICAL MARKERS; COMMUNITY HEALTH SERVICES; CREATININE; EARLY DIAGNOSIS; FEMALE; GLOMERULAR FILTRATION RATE; HEMATURIA; HUMANS; INTERNATIONAL COOPERATION; KIDNEY DISEASES; MALE; MASS SCREENING; MEXICO; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; POVERTY; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; PROTEINURIA; REAGENT KITS, DIAGNOSTIC; REAGENT STRIPS; SOCIETIES, MEDICAL; YOUNG ADULT;

EID: 77749242501     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Secretaria de Salud. Salud: Mexico 2004. Información para la rendición de cuentas. 2nd ed. Mexico City: Secretaria de Salud; 2005.
2. Frenk J, Gonzalez Block MA, Knaul F, Solis F, Villagomez FA. La Seguridad Social en Salud: Perspectivas para la Reforma. La Seguridad Social en Mexico. Mexico City: Fondo de Cultura Economica; 1999:35-102.
3. Jafar TH. The growing burden of chronic kidney disease in Pakistan. N Engl J Med. 2006;354:995-997.
4. US Renal Data System. Atlas of end-stage renal disease in the United States: international comparisons. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
5. Instituto Nacional de Estadística y Geografía. Jalisco: información estadistica: defunciones generales por principales causas de defunción. 2006. Available at: http://www.inegi.gob.mx/. Accessed June 10, 2009.
6. Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, et al. Renal replacement therapy among disadvantaged populations in Mexico: a report from the Jalisco Dialysis and Transplant Registry (REDTJAL). Kidney Int Suppl. 2005;(Suppl 97):S58-S61.
7. Garcia-Garcia G, Briseno-Renteria G, Luquin-Arellan VH, Gao Z, Gill J, Tonelli M. Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol. 2007;18:1922-1927.
8. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
9. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(Suppl 1):S76.
10. Hosmer DW, Lemeshow S. Model building strategies: applied logistic regression. New York: Wiley Interscience; 2000:91-142.
11. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109-2118.
12. Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333:1047.
13. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2003;14(Suppl 2):S131-S138.
14. Li PK, Kwan BC, Leung CB, et al. Prevalence of silent kidney disease in Hong Kong: the Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney Int Suppl. 2005;(94):S36-S40.
15. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907-1917.
16. Aguilar-Salinas CA, Velazquez MO, Gomez-Perez FJ, et al. Characteristics of patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. Diabetes Care. 2003;26:2021-2026.
17. Velazquez-Monroy O, Rosas PM, Lara EA, et al. Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico: final outcomes from the National Health Survey 2000. Arch Cardiol Mex. 2003;73:62-77.
18. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22-35.
19. Dirks JH, de Zeeuw D, Agarwal SK, et al. Prevention of chronic kidney and vascular disease: toward global health equity: the Bellagio 2004 Declaration. Kidney Int Suppl. 2005;(98):S1-S6.
20. Dirks JH, Robinson SW, Alderman M, et al. Meeting report on the Bellagio Conference: 'prevention of vascular diseases in the emerging world: an approach to global health equity'. Kidney Int. 2006;70:1397-1402.
21. Mani MK. Nephrologists sans frontieres: preventing chronic kidney disease on a shoestring. Kidney Int. 2006;70:821-823.
22. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
24. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
26. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565-570.
27. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605-1613.
28. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165-2175.